Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs

被引:38
作者
Saxon, AJ [1 ]
McCarty, D
机构
[1] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA
[2] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98108 USA
[3] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA
关键词
buprenorphine; pharmacotherapy; adoption of innovations;
D O I
10.1016/j.pharmthera.2005.06.014
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The adoption of pharmacotherapies for the treatment of alcohol and drug use disorders has progressed slowly despite the approval of new and effective medications. This paper begins with overviews of the prevalence of alcohol and drug abuse and dependence, the costs of addiction to the nation, and the value of treatment services. The role of pharmacotherapy in the treatment of addictive diseases is examined, and factors that affect the adoption and use of medications for alcohol and drug treatment are identified and discussed. Investigations that tested the effectiveness of buprenorphine for treatment of opioid dependence in new settings illustrate physician and counselor training and mentorship strategies that may promote the adoption of medications in the treatment of alcohol and drug use disorders. The paper concludes with a discussion of barriers and ways to surmount the barriers and to foster greater use of medications in alcohol and drug treatment. (c) 2005 Published by Elsevier Inc.
引用
收藏
页码:119 / 128
页数:10
相关论文
共 78 条
[1]   Bringing buprenorphine-naloxone detoxification to community treatment providers: The NIDA Clinical Trials Network field experience [J].
Amass, L ;
Ling, W ;
Freese, TE ;
Reiber, C ;
Annon, JJ ;
Cohen, AJ ;
McCarty, D ;
Reid, MS ;
Brown, LS ;
Clark, C ;
Ziedonis, DM ;
Krejci, J ;
Stine, S ;
Winhusen, T ;
Brigham, G ;
Babcock, D ;
Muir, JA ;
Buchan, BJ ;
Horton, T .
AMERICAN JOURNAL ON ADDICTIONS, 2004, 13 :S42-S66
[2]  
[Anonymous], 1998, JAMA, V280, P1936
[3]  
[Anonymous], 1998, BRIDG GAP PRACT RES
[4]  
[Anonymous], 2000, Cochrane Database of Systematic Reviews, DOI [DOI 10.1002/14651858.CD000336, 10.1002/14651858.CD000336]
[5]   French field experience with buprenorphine [J].
Auriacombe, M ;
Fatséas, M ;
Dubernet, J ;
Daulouède, JP ;
Tignol, J .
AMERICAN JOURNAL ON ADDICTIONS, 2004, 13 :S17-S28
[6]   The cost-effectiveness of methadone maintenance as a health care intervention [J].
Barnett, PG .
ADDICTION, 1999, 94 (04) :479-488
[7]   The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States [J].
Barnett, PG ;
Zaric, GS ;
Brandeau, ML .
ADDICTION, 2001, 96 (09) :1267-1278
[8]   Methadone maintenance and drug-related crime [J].
Bell, J ;
Mattick, R ;
Hay, A ;
Chan, J ;
Hall, W .
JOURNAL OF SUBSTANCE ABUSE, 1997, 9 :15-25
[9]   Cocaine: Pathophysiology and clinical toxicology [J].
Boghdadi, MS ;
Henning, RJ .
HEART & LUNG, 1997, 26 (06) :466-483
[10]  
BRIGHAM G, 2004, COLL PROBL DRUG DEP